Fadogia Agrestis

Honestly, we do not know. There are zero published human clinical trials testing fadogia agrestis for testosterone. All the excitement is based on a single 2005 rat study (Yakubu et al.) that showed dose-dependent testosterone increases. While the proposed mechanism (LH-mimetic saponin activity) is biologically plausible, animal results frequently fail to replicate in humans. Many compounds that dramatically alter hormones in rodents have no meaningful effect in people. Until human RCTs are published, fadogia remains an unproven supplement. This is the honest answer that most supplement marketing omits.

The safety profile is genuinely unknown in humans. The concerning signal comes from Yakubu et al. (2008), which found testicular toxicity markers in rats at higher doses — including lipid peroxidation, heavy metal accumulation in testicular tissue, and histopathological changes (seminiferous tubule damage). These findings were dose-dependent, with 100 mg/kg being the worst. While the human-equivalent dose is debated, the lack of any human safety data means you are accepting unknown risk. Cycling (3 weeks on / 1 week off) and regular blood work are the minimum precautions.

There is no clinically validated human dosage. The commonly cited 300-600mg/day range is an extrapolation from the rat study doses, adjusted for body weight differences between species. The lower end (300mg/day) is more conservative and carries theoretically less risk. Some people take 600mg/day, but there is no evidence that higher doses produce better results in humans, and the toxicity data in rats was dose-dependent. If you choose to use fadogia, starting at 300mg/day and cycling 3 weeks on / 1 week off is the most cautious approach.

This is the most popular stack, popularized by Andrew Huberman. The theoretical rationale is complementary mechanisms: fadogia may stimulate LH production (upstream signal) while tongkat ali may reduce SHBG (freeing bound testosterone) and support HPG axis function. However, this specific combination has never been tested in a human clinical trial. Tongkat ali on its own has substantially more evidence behind it (multiple human RCTs showing 15-37% testosterone increases). If you must choose one, tongkat ali has the stronger evidence base. If stacking, the typical protocol is fadogia 300-600mg + tongkat ali 200-400mg, cycled.

They have different proposed mechanisms. Fadogia agrestis is thought to act as an LH-mimetic — its saponins may directly stimulate Leydig cells in the testes to produce testosterone, similar to how luteinizing hormone works. Tongkat ali (Eurycoma longifolia) appears to work through SHBG reduction (freeing bound testosterone), mild HPG axis support, and cortisol modulation. The critical difference is evidence quality: tongkat ali has multiple published human RCTs, while fadogia has zero. Tongkat ali also has a much longer history of traditional use (centuries in Southeast Asia) and better-characterized safety data.

Andrew Huberman discussed fadogia agrestis on his podcast as part of a testosterone-support stack, citing the Yakubu 2005 study and the theoretical LH-mimetic mechanism. To his credit, he has noted the limited evidence and recommended cycling and blood work monitoring. However, the podcast format amplified interest far beyond what the evidence warrants. A single animal study in rats, with a follow-up showing toxicity, would not normally generate mainstream supplement adoption. Huberman's recommendation should be understood as an informed hypothesis, not a clinical endorsement — and he would likely agree with that characterization.

At minimum: total testosterone, free testosterone, LH, FSH, liver enzymes (ALT, AST, GGT), kidney function (BUN, creatinine, eGFR), and a complete blood count. Get baseline values before starting, then retest at 8 weeks. The liver and kidney markers are important because we have no human toxicology data — you are essentially running an n=1 experiment on yourself, and organ function monitoring is the minimum responsible precaution. If any markers move in a concerning direction, discontinue immediately.

There is absolutely no data on fadogia agrestis in women — not even animal studies. Given that the proposed mechanism involves LH-mimetic activity and direct testicular stimulation, the relevance to female physiology is unclear. Women naturally produce testosterone (at much lower levels than men), and LH plays a role in ovarian function, but the effects of fadogia on the female HPG axis are completely unknown. We cannot recommend fadogia for women. If you are a woman seeking natural testosterone support, ashwagandha (KSM-66) and adequate sleep, resistance training, and nutrition have actual evidence behind them.

This is the most important question, and the honest answer is: probably not for most people. The evidence is extraordinarily thin — one animal study showing efficacy, with a follow-up showing toxicity. No human trials. No standardized extracts. Questionable supply chain quality. Meanwhile, the fundamentals (sleep optimization, resistance training, adequate nutrition, stress management, vitamin D, zinc, magnesium) have robust human evidence and essentially zero risk. If your sleep is not optimized, your training is inconsistent, and your diet is poor, fadogia agrestis is a distraction from what actually moves the needle. If everything else is truly dialed in and you want to experiment, do so with cycling, blood work, and the understanding that you are an early adopter of an unproven compound.

We genuinely do not know the answer for humans. In the Yakubu 2005 rat study, testosterone increases were observed over a 28-day period. Anecdotal reports from human users vary widely — some claim effects within 1-2 weeks, others notice nothing. Given that there are no human pharmacokinetic studies, onset of action, optimal duration, and time to steady state are all unknown. If you notice no subjective benefit after two full cycles (6 weeks on), it is reasonable to conclude that it is not working for you and discontinue.